136 related articles for article (PubMed ID: 8663420)
1. A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts.
Kurokawa M; Tanaka T; Tanaka K; Hirano N; Ogawa S; Mitani K; Yazaki Y; Hirai H
J Biol Chem; 1996 Jul; 271(28):16870-6. PubMed ID: 8663420
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H
Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911
[TBL] [Abstract][Full Text] [Related]
3. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
4. Solution properties of the free and DNA-bound Runt domain of AML1.
Wolf-Watz M; Xie XQ; Holm M; Grundström T; Härd T
Eur J Biochem; 1999 Apr; 261(1):251-60. PubMed ID: 10103057
[TBL] [Abstract][Full Text] [Related]
5. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
6. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
Tahirov TH; Inoue-Bungo T; Morii H; Fujikawa A; Sasaki M; Kimura K; Shiina M; Sato K; Kumasaka T; Yamamoto M; Ishii S; Ogata K
Cell; 2001 Mar; 104(5):755-67. PubMed ID: 11257229
[TBL] [Abstract][Full Text] [Related]
7. Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues.
Akamatsu Y; Ohno T; Hirota K; Kagoshima H; Yodoi J; Shigesada K
J Biol Chem; 1997 Jun; 272(23):14497-500. PubMed ID: 9169404
[TBL] [Abstract][Full Text] [Related]
8. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
9. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias.
Mao S; Frank RC; Zhang J; Miyazaki Y; Nimer SD
Mol Cell Biol; 1999 May; 19(5):3635-44. PubMed ID: 10207087
[TBL] [Abstract][Full Text] [Related]
10. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
[TBL] [Abstract][Full Text] [Related]
11. The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding.
Bäckström S; Wolf-Watz M; Grundström C; Härd T; Grundström T; Sauer UH
J Mol Biol; 2002 Sep; 322(2):259-72. PubMed ID: 12217689
[TBL] [Abstract][Full Text] [Related]
12. Mutational analyses of the AML1 gene in patients with myelodysplastic syndrome.
Imai O; Kurokawa M; Izutsu K; Hangaishi A; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Leuk Lymphoma; 2002 Mar; 43(3):617-21. PubMed ID: 12002768
[TBL] [Abstract][Full Text] [Related]
13. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
[TBL] [Abstract][Full Text] [Related]
14. PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.
Bae SC; Ogawa E; Maruyama M; Oka H; Satake M; Shigesada K; Jenkins NA; Gilbert DJ; Copeland NG; Ito Y
Mol Cell Biol; 1994 May; 14(5):3242-52. PubMed ID: 8164679
[TBL] [Abstract][Full Text] [Related]
15. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
16. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis.
Imai Y; Kurokawa M; Izutsu K; Hangaishi A; Takeuchi K; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Blood; 2000 Nov; 96(9):3154-60. PubMed ID: 11049997
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta.
Warren AJ; Bravo J; Williams RL; Rabbitts TH
EMBO J; 2000 Jun; 19(12):3004-15. PubMed ID: 10856244
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia.
Miyoshi H; Ohira M; Shimizu K; Mitani K; Hirai H; Imai T; Yokoyama K; Soeda E; Ohki M
Nucleic Acids Res; 1995 Jul; 23(14):2762-9. PubMed ID: 7651838
[TBL] [Abstract][Full Text] [Related]
20. An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms.
Tanaka T; Tanaka K; Ogawa S; Kurokawa M; Mitani K; Yazaki Y; Shibata Y; Hirai H
Leukemia; 1997 Apr; 11 Suppl 3():299-302. PubMed ID: 9209372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
